| Accession |
PRJCA012014 |
| Title |
A Phase I/II Study of FGFR4 Inhibitor EVER4010001 in Combination with PD-1 Inhibitor Pembrolizumab in Patients with Advanced Solid Tumors with Dose Escalation and Expansion to Selected Indications |
| Relevance |
Medical |
| Data types |
PK and biomarker result data
|
| Organisms |
Homo sapiens
|
| Description |
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of EVER4010001 in combination with Pembrolizumab.Secondary Objectives: To characterize the pharmacokinetics (PK) and individual drug exposure of EVER4010001 in combination with Pembrolizumab. To assess preliminary anti-tumor efficacy of EVER4010001 in combination with Pembrolizumab. To assess the safety and tolerability of EVER4010001 in combination with Pembrolizumab. To explore the predictive biomarkers. |
| Sample scope |
human blood |
| Release date |
2024-09-20 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| EverNov Medicines (Hengqin, Zhuhai) Co., Ltd
|
|
N/A
|
|
|
|
| Submitter |
Yingjun
Shi (yingjun.shi@everestmedicines.com)
|
| Organization |
EverNov Medicines (Hengqin, Zhuhai) Co., Ltd |
| Submission date |
2022-09-20 |
